Methamphetamine associated psychosis and treatment with risperidone and halopridol

Phase 2

• Conditions: Methamphetamine-associated psychosis.; Mental and behavioural disorders due to use of other stimulants, including caffeine

• Registration Number: IRCT201507155280N19
• Lead Sponsor: Vice chancellor for research of University of Social Welfare and Rehabilitation Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Patient in the age range 18 to 60; signing informed consent. Exclusion criteria: presence of other psychiatric disorders; abusing of other psycho stimulant drugs; comorbid neurological disorders; mental retardation.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Methamphetamine-associated psychosis. Timepoint: Baseline, the first week after intervention, the second week after intervention, the third week after intervention, the first week after finishing the intervention. Method of measurement: Scale of Assessment of Positive Symptoms (SAPS).